Intrinsic Antibacterial Activity of Xeruborbactam <i>In Vitro</i> : Assessing Spectrum and Mode of Action-Reference-Cited by-同舟云学术

Intrinsic Antibacterial Activity of Xeruborbactam In Vitro : Assessing Spectrum and Mode of Action

Published:2022-10-18 Issue:10 Volume:66 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Sun Dongxu¹,Tsivkovski Ruslan¹,Pogliano Joe²³,Tsunemoto Hannah²,Nelson Kirk¹,Rubio-Aparicio Debora¹,Lomovskaya Olga¹^ORCID

Affiliation:

1. Qpex Biopharma, Inc., San Diego, California, USA

2. Linnaeus Biosciences, Inc., San Diego, California, USA

3. University of California, San Diego, San Diego, California, USA

Abstract

Xeruborbactam (formerly QPX7728) is a cyclic boronate inhibitor of numerous serine and metallo-beta-lactamases. At concentrations generally higher than those required for beta-lactamase inhibition, xeruborbactam has direct antibacterial activity against some Gram-negative bacteria, with MIC 50 /MIC 90 values of 16/32 μg/mL and 16/64 μg/mL against carbapenem-resistant Enterobacterales and carbapenem-resistant Acinetobacter baumannii , respectively (the MIC 50 /MIC 90 values against Pseudomonas aeruginosa are >64 μg/mL).

Funder

HHS | Biomedical Advanced Research and Development Authority

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/aac.00879-22

Reference47 articles.

1. A review of the antimicrobial activity of clavulanate

2. Sulbactam: a beta-lactamase inhibitor;Noguchi JK;Clin Pharm,1988

3. In VitroActivity of Ceftazidime-Avibactam Combination inIn VitroCheckerboard Assays